David Goodman-Meza

David Goodman-Meza

Auto-generated profile, based on publicly available information

David Goodman-Meza

Kirby Institute, University of New South Wales, Sydney, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
MMM. Khalid Mojadidi
M. Khalid Mojadidi
SRScott C. Roberts
Scott C. Roberts
JWJared S. Winoker
Jared S. Winoker
Jorge E RomeroJorge E Romero
Jorge E Romero
DGDavid Goodman-Meza
David Goodman-Meza
JTJonathan M. Tobis
Jonathan M. Tobis

22 September 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DGDavid Goodman-Meza
David Goodman-Meza
ARAkos Rudas
Akos Rudas
JCJeffrey N. Chiang
Jeffrey N. Chiang
PAPaul Adamson
Paul Adamson
JEJoseph Ebinger
Joseph Ebinger
VMVladimir Manuel
Vladimir Manuel
Worldwide, testing capacity for SARS-CoV-2 is limited and bottlenecks in the scale up of polymerase chain reaction (PCR-based testing exist. Our aim was to develop and evaluate a machine learning algorithm to diagnose COVID-19 in the inpatient setting. The algorithm was based on basic demographic and laboratory features to serve as a screening tool at hospitals where testing is scarce or unavailable. We used retrospectively collected data from the UCLA Health System in Los Angeles, California. We included all emergency room or inpatient cases receiving SARS-CoV-2 PCR testing who also had a set of ancillary laboratory features (n = 1,455) between 1 March 2020 and 24 May 2020. We tested seven machine learning models and used a combination of those models for the final diagnostic classification. In the test set (n = 392), our combined model had an area under the receiver operator curve of 0.91 (95% confidence interval 0.87–0.96). The model achieved a sensitivity of 0.93 (95% CI 0.85–0.98), specificity of 0.64 (95% CI 0.58–0.69). We found that our machine learning algorithm had excellent diagnostic metrics compared to SARS-CoV-2 PCR. This ensemble machine learning algorithm to diagnose COVID-19 has the potential to be used as a screening tool in hospital settings where PCR testing is scarce or unavailable.

3 February 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OJOluwadamilola Jolayemi
Oluwadamilola Jolayemi
LBLaura M. Bogart
Laura M. Bogart
ESErik D. Storholm
Erik D. Storholm
DGDavid Goodman-Meza
David Goodman-Meza
ERElena Rosenberg-Carlson
Elena Rosenberg-Carlson
RLRaphael J. Landovitz
Raphael J. Landovitz
Long-acting injectable (LAI) antiretroviral therapy (ART) is a novel HIV treatment option for people with HIV. The first LAI ART regimen for HIV treatment received regulatory approval in the United States in January 2021. In February 2020, we collected qualitative data from 18 consumers and 23 clinical and non-clinical stakeholders to catalog anticipated individual-consumer, healthcare system, and structural levels barriers and facilitators to LAI ART implementation in Los Angeles County, California. Thematic analysis was guided by the CFIR implementation science model. CFIR constructs of intervention characteristics, individual characteristics, outer and inner setting, intervention characteristics, and implementation process emerged in analysis. Under intervention characteristics, anticipated facilitators included the relative advantage of LAI ART over pills for adherence and reduced treatment management burden and related anxiety; anticipated barriers included non-adherence to injection appointments, concerns of developing HIV resistance, discomfort with injection and cost. Anticipated facilitators based on individual characteristics included overall acceptability based on knowledge and positive beliefs about LAI ART. Participant noted several characteristics of the outer setting that could negatively impact implementation, such as medical mistrust, external policies, and LAI ART eligibility (i.e., to be virally suppressed prior to initiation). Participants were optimistic about the potential to decrease stigma but expressed that provider willingness for adoption could be hindered by challenges in organizational inner setting related to payment authorizations, increased staffing needs, medication procurement and storage, and provider and healthcare system readiness. Results from this pre-implementation study may inform rollout and scale-up of LAI ART in Los Angeles County.

1 November 2019 in Substance Abuse and Rehabilitation
Verified
Journal Article
Open access
PDF file
WLWalter Ling
Walter Ling
SSSteve Shoptaw
Steve Shoptaw
DGDavid Goodman-Meza
David Goodman-Meza
Buprenorphine has pharmacologic advantages over methadone, especially buprenorphine’s better safety profile. The true significance of buprenorphine’s introduction lies in returning the care of those suffering from opioid use disorder (OUD) to the hands of the physician. The clinical success of buprenorphine has been meager, in part because most physicians have not been exposed to treating these patients. For physicians inclined to treat OUD, the barriers to buprenorphine’s implementation have been onerous and largely counter to the norms of medical practice. Some notable concerns pertain to buprenorphine’s clinical pharmacology like street diversion, unintended use and accidental poisoning. Recently, injectable buprenorphine preparations have been introduced to mitigate these latter shortcomings. Yet, the injectable preparations’ clinical and commercial success has fallen far short of expectation. Here, we review the clinical pharmacology of these products and their expected clinical advantages for the manufacturers, clinicians, policy makers and patients, and offer our perspective, as clinicians and researchers, on how things can improve. Questions remain whether clinicians are willing to overcome barriers to treat OUD using these medications.

22 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAna C. Monteiro
Ana C. Monteiro
RSRajat Suri
Rajat Suri
IEIheanacho O. Emeruwa
Iheanacho O. Emeruwa
RSRobert J. Stretch
Robert J. Stretch
RCRoxana Y. Cortes-Lopez
Roxana Y. Cortes-Lopez
NQNida Qadir
Nida Qadir
Purpose: To describe the trajectory of respiratory failure in COVID-19 and explore factors associated with risk of invasive mechanical ventilation (IMV). Materials and methods: A retrospective, observational cohort study of 112 inpatient adults diagnosed with COVID-19 between March 12 and April 16, 2020. Data were manually extracted from electronic medical records. Multivariable and Univariable regression were used to evaluate association between baseline characteristics, initial serum markers and the outcome of IMV. Results: Our cohort had median age of 61 (IQR 45–74) and was 66% male. In-hospital mortality was 6% (7/112). ICU mortality was 12.8% (6/47), and 18% (5/28) for those requiring IMV. Obesity (OR 5.82, CI 1.74–19.48), former (OR 8.06, CI 1.51–43.06) and current smoking status (OR 10.33, CI 1.43–74.67) were associated with IMV after adjusting for age, sex, and high prevalence comorbidities by multivariable analysis. Initial absolute lymphocyte count (OR 0.33, CI 0.11–0.96), procalcitonin (OR 1.27, CI 1.02–1.57), IL-6 (OR 1.17, CI 1.03–1.33), ferritin (OR 1.05, CI 1.005–1.11), LDH (OR 1.57, 95% CI 1.13–2.17) and CRP (OR 1.13, CI 1.06–1.21), were associated with IMV by univariate analysis. Conclusions: Obesity, smoking history, and elevated inflammatory markers were associated with increased need for IMV in patients with COVID-19.

1 September 2015 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
EPEileen V. Pitpitan
Eileen V. Pitpitan
LSLaramie R. Smith
Laramie R. Smith
DGDavid Goodman-Meza
David Goodman-Meza
KTKarla Torres
Karla Torres
SSShirley J. Semple
Shirley J. Semple
TPThomas L. Patterson
Thomas L. Patterson